Home » Topics » Medical technology

Medical technology
RSS

ZymoGenetics, Novo Deal: $77M For Blood Clot-Boosters Program

Oct. 6, 2004

Genelabs Falls 65 Percent On Failed Prestara Trial In Lupus

Oct. 6, 2004

CytRx Buys Hungarian Firm; $3M Gets ALS Drug, Others

Oct. 6, 2004

Biota, Consortium Bring In $10M In NIAID Grant Money

Oct. 6, 2004

FDA Asks For More Time On MS-325 Review; EPIX Sinks

Oct. 6, 2004

By Brady Huggett

Bavarian Nordic, Acambis Stay In Smallpox Vaccine Stockpile Race

Oct. 6, 2004

By Cormac Sheridan

Chloroquine-Resistance Secrets Could Beget New Antimalarials

Oct. 6, 2004

By Sharon Kingman

VASTox Seeking £15M On AIM For Chemical Genomics

Oct. 6, 2004

CeNeS, With Phase III Data Under Belt, Raises £11.4M

Oct. 6, 2004

Inhibitory Peptides May Be New Weapon Against Type II Diabetes

Oct. 6, 2004

By Anette Breindl

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...